Logo
Atomo Diagnostics Investor Hub

About us

Where the idea came from

A light bulb moment

While John was exploring parts of the market where usability was poorly delivered, his youngest daughter was born and needed intensive medical care for the first two years of her life. He watched doctors struggle to collect blood from her arm, then learned the test only needed a tiny drop.

That was the moment. We set out to build a better, less invasive way to collect a blood sample, and that principle still drives every device we design.

Why now

A pivotal moment for healthcare

Consumer acceptance of telemedicine and the appetite for faster information have driven real demand for rapid point of care diagnostics. Since the pandemic, consumers, clinicians and regulators have all become more comfortable with testing outside clinical settings.

Consumer rapid testing is now a standard ranged item in pharmacy and retail, and public health programmes are adopting at home and self test technology to improve efficiency and reduce the stigma attached to testing for certain infectious diseases.

The shareholder view

What our history means if you own AT1

Fifteen years of device engineering is not just a nice story. It is the reason our cost to launch a new test is low, our approvals are hard to replicate and our partners keep coming back. FY26 is where that started to show in the numbers.

Low cost to add a test

Every new indication runs on hardware we have already validated and tooled. Active syphilis reached the end of development, and liver function entered the pipeline, without a new platform build behind either of them.

Approvals are the barrier

TGA, WHO Prequalification, CE Mark, FDA, ANVISA and Health Canada registrations take years and real money. We hold them already, so entering a new market is a commercial decision rather than a regulatory project.

Partners carry our volume

Diagnostic companies put their own tests on our cassettes, so their commercial success adds volume to our line without us funding their sales effort. That channel grew 209% in FY26.

These solutions reduce error rates, improve care and have significant commercial potential in both the developing world and in developed healthcare markets.

Dr Curt LaBelleGlobal Health Fund

The investment case

Why invest in Atomo

Products already selling, approvals on four continents, technology we own outright and a pipeline that runs on the same platform. Here is the full picture.